Developing of Cubas biotechnology is up and going
Cubas biotechnology registered growths of 75 and 87 million pesos in the last two years, while important results are being achieved during the present year.
This scientific activity yields a number of products that by far contribute to ensure health quality for the population at the time its the second export line in the country. Tech transfers to enable manufacturing in other countries are in process.
Amidst the medications Cuba produces are the Anti-hepatitis B recombinant vaccine, a leading product accepted in the World Health Organization campaigns that accounts for more than 170 million manufactured doses.
Other notable vaccines are the Meningococcal, unique of its kind in the world and the Haemophilic influenza type B vaccine, the first one produced through chemical synthesis.